Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Research output: Contribution to journal › Article › Academic › peer-review

Access to Document

@article{8a8f88185cfc40568351307a8a6c237e,

title = "Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.",

author = "J. Golay and \{Da Roit\}, F. and L. Bologna and C. Ferrara and J.H.W. Leusen and A. Rambaldi and C Klein and M. Introna",

year = "2013",

doi = "10.1182/blood-2013-05-504043",

language = "English",

volume = "122",

pages = "3482--3491",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "20",

}

TY - JOUR

T1 - Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

AU - Golay, J.

AU - Da Roit, F.

AU - Bologna, L.

AU - Ferrara, C.

AU - Leusen, J.H.W.

AU - Rambaldi, A.

AU - Klein, C

AU - Introna, M.

PY - 2013

Y1 - 2013

U2 - 10.1182/blood-2013-05-504043

DO - 10.1182/blood-2013-05-504043

M3 - Article

C2 - 24106207

SN - 0006-4971

VL - 122

SP - 3482

EP - 3491

JO - Blood

JF - Blood

IS - 20

ER -